Healthcare-associated infections in critical COVID-19 patients in Tunis: epidemiology, risk factors, and outcomes.

COVID-19 critical care epidemiology healthcare-associated infections prognosis

Journal

Acute and critical care
ISSN: 2586-6060
Titre abrégé: Acute Crit Care
Pays: Korea (South)
ID NLM: 101726905

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 02 06 2023
accepted: 26 09 2023
medline: 6 12 2023
pubmed: 6 12 2023
entrez: 5 12 2023
Statut: ppublish

Résumé

Coronavirus disease 2019 (COVID-19) pandemic disrupted adherences to healthcare-associated infection (HAI) prevention protocols. Herein, we studied the characteristics of all HAIs occurring in critically ill COVID-19 patients. A retrospective, single-center cohort of critical COVID-19 patients during 2021. Microbiological samples were collected if HAI was suspected. We analyzed all factors that could potentially induce HAI, using septic shock and mortality as endpoints. Sixty-four among 161 included patients (39.7%) presented a total of 117 HAIs with an incidence density of 69.2 per 1,000 hospitalization days. Compared to the prior COVID-19 period (2013-2019), the identification of HAI increased in 2021. HAIs were classified into ventilator-associated pneumonia (VAP; n=38), bloodstream infection (n=32), urinary tract infection (n=24), catheter-related infection (n=12), and fungal infection (n=11). All HAIs occurred significantly earlier in the post-COVID-19 period (VAP: 6 vs. 10 days, P=0.045, in 2017 and 2021). Acinetobacter baumannii (39.5%) and Klebsiella pneumoniae (27%) were the most commonly isolated pathogens that exhibited a multidrug-resistant (MDR) profile, observed in 89% and 64.5%, respectively. The HAI factors were laboratory abnormalities (odds ratio [OR], 6.4; 95% confidence interval [CI], 2.3-26.0), cumulative steroid dose (OR, 1.9; 95% CI, 1.3-4.0), and invasive procedures (OR, 20.7; 95% CI, 5.3-64.0). HAI was an independent factor of mortality (OR, 8.5; P=0.004). During the COVID-19 era, the incidence of HAIs increased and MDR isolates remained frequent. A severe biological inflammatory syndrome, invasive devices, and elevated cumulative steroid dosages were related to HAIs. HAI was a significant death factor.

Sections du résumé

BACKGROUND BACKGROUND
Coronavirus disease 2019 (COVID-19) pandemic disrupted adherences to healthcare-associated infection (HAI) prevention protocols. Herein, we studied the characteristics of all HAIs occurring in critically ill COVID-19 patients.
METHODS METHODS
A retrospective, single-center cohort of critical COVID-19 patients during 2021. Microbiological samples were collected if HAI was suspected. We analyzed all factors that could potentially induce HAI, using septic shock and mortality as endpoints.
RESULTS RESULTS
Sixty-four among 161 included patients (39.7%) presented a total of 117 HAIs with an incidence density of 69.2 per 1,000 hospitalization days. Compared to the prior COVID-19 period (2013-2019), the identification of HAI increased in 2021. HAIs were classified into ventilator-associated pneumonia (VAP; n=38), bloodstream infection (n=32), urinary tract infection (n=24), catheter-related infection (n=12), and fungal infection (n=11). All HAIs occurred significantly earlier in the post-COVID-19 period (VAP: 6 vs. 10 days, P=0.045, in 2017 and 2021). Acinetobacter baumannii (39.5%) and Klebsiella pneumoniae (27%) were the most commonly isolated pathogens that exhibited a multidrug-resistant (MDR) profile, observed in 89% and 64.5%, respectively. The HAI factors were laboratory abnormalities (odds ratio [OR], 6.4; 95% confidence interval [CI], 2.3-26.0), cumulative steroid dose (OR, 1.9; 95% CI, 1.3-4.0), and invasive procedures (OR, 20.7; 95% CI, 5.3-64.0). HAI was an independent factor of mortality (OR, 8.5; P=0.004).
CONCLUSIONS CONCLUSIONS
During the COVID-19 era, the incidence of HAIs increased and MDR isolates remained frequent. A severe biological inflammatory syndrome, invasive devices, and elevated cumulative steroid dosages were related to HAIs. HAI was a significant death factor.

Identifiants

pubmed: 38052509
pii: acc.2023.00773
doi: 10.4266/acc.2023.00773
doi:

Types de publication

Journal Article

Langues

eng

Pagination

425-434

Références

Ann Intensive Care. 2020 Sep 7;10(1):119
pubmed: 32894364
Chest. 2021 Aug;160(2):454-465
pubmed: 33857475
Infect Drug Resist. 2018 Nov 15;11:2321-2333
pubmed: 30532565
Clin Infect Dis. 2021 Jul 15;73(2):e445-e454
pubmed: 32651997
Lancet Infect Dis. 2018 May;18(5):490-492
pubmed: 29695352
BMC Health Serv Res. 2018 Jul 4;18(1):521
pubmed: 29973258
Intensive Care Med. 2020 Dec;46(12):2168-2183
pubmed: 33175277
Curr Opin Clin Nutr Metab Care. 1999 Jan;2(1):79-82
pubmed: 10453334
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Eur J Clin Microbiol Infect Dis. 2021 Mar;40(3):495-502
pubmed: 33389263
Risk Manag Healthc Policy. 2020 Nov 13;13:2593-2599
pubmed: 33223859
Lancet Infect Dis. 2019 May;19(5):463-464
pubmed: 31034384
J Prim Care Community Health. 2020 Jan-Dec;11:2150132720943331
pubmed: 32686571
Infect Control Hosp Epidemiol. 2020 Aug;41(8):982-983
pubmed: 32279676
Clin Infect Dis. 2020 Sep 12;:
pubmed: 32918466
Tunis Med. 2017 Mar;95(3):179-184
pubmed: 29446811
J Infect. 2020 Aug;81(2):266-275
pubmed: 32473235
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Crit Care. 2022 Aug 3;26(1):236
pubmed: 35922860
Infect Control Hosp Epidemiol. 2022 Sep;43(9):1184-1193
pubmed: 34308805
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Clin Microbiol Infect. 2021 Jan;27(1):83-88
pubmed: 32745596
Diabetes Care. 2019 May;42(5):832-840
pubmed: 30923164
Am J Infect Control. 2020 Oct;48(10):1211-1215
pubmed: 32093978
Antimicrob Resist Infect Control. 2021 Jun 4;10(1):87
pubmed: 34088341
J Hosp Infect. 2021 Jan;107:95-97
pubmed: 33217490

Auteurs

Ahlem Trifi (A)

Medical Intensive Care Unit, La Rabta Hospital, Tunis, Tunisia.

Selim Sellaouti (S)

Medical Intensive Care Unit, La Rabta Hospital, Tunis, Tunisia.

Asma Mehdi (A)

Medical Intensive Care Unit, La Rabta Hospital, Tunis, Tunisia.

Lynda Messaoud (L)

Medical Intensive Care Unit, La Rabta Hospital, Tunis, Tunisia.

Eya Seghir (E)

Medical Intensive Care Unit, La Rabta Hospital, Tunis, Tunisia.

Badis Tlili (B)

Medical Intensive Care Unit, La Rabta Hospital, Tunis, Tunisia.

Sami Abdellatif (S)

Medical Intensive Care Unit, La Rabta Hospital, Tunis, Tunisia.

Classifications MeSH